Medicilon Assists Xuanzhu Biopharmaceutical's KM501, a First Double-antibody ADC Drug that Completely Knocks Out Fucose, has been Approved for Clinical Trials

Recently, Xuanzhu Biopharmaceutical (Xuanzhu) and its wholly-owned subsidiary Beijing Xuanzhu Bio, obtained clinical trial approval for the double-antibody ADC drug KM501 (No.: 2023LP00278). This product is suitable for the treatment of advanced/metastatic solid tumors with positive/expression, amplification or mutation of HER2, including related advanced tumors with low expression of HER2. The drug is the world's first double-antibody ADC drug that completely knocks out fucose, and is expected to become the "Best in Class" drug.

Shanghai Medicilon Inc. (Medicilon), as a partner of Xuanzhu, provided KM501 with GLP-compliant preclinical research services based on the Medicilon Antibody Development Service Platform, including pharmacokinetic studies and safety evaluation. This has won time for Xuanzhu to advance the KM501 into clinical research as fast as possible.

Medicilon Antibody Drug Conjugate (ADC) R&D Service Platform
The whole process facilitates the preclinical development of ADC drugs

As a one-stop pharmaceutical preclinical R&D service platform CRO, Medicilon has continuously iterated new drug R&D technologies for 19 years. In the field of ADC drug research and development, Medicilon provides clients with one-stop preclinical research services such as ADC Payloads synthesis, ADC drug conjugation, ADC pharmacodynamics evaluation, ADC pharmacokinetics evaluation and ADC safety evaluation.

Since the establishment of Medicilon Antibody Drug Conjugate (ADC) R&D Service Platform, Medicilon has accumulated many well-known world wide pharmaceutical companies and scientific research institutions, successfully assisted in the clinical approval of ADC projects of innovative pharmaceutical companies such as Bio-Thera and DAC Biotech, and won the continuous trust and praise of clients and long-term collaboration. Medicilon successfully assisted Xuanzhu’s KM501 in clinical approval, which provided valuable experience for the Medicilon Antibody Drug Conjugate (ADC) R&D Service Platform to assist in the preclinical research and development of more new generation ADC drugs.

Medicilon congratulates Xuanzhu’s KM501 on the clinical approval, and looks forward to the smooth clinical progress of the drug, providing a competitive new choice for patients with solid tumors. The era of new drugs is moving forward. Medicilon's latest technology platform will continue to help global clients develop new drugs through high-tech, high-efficiency, high-quality, and cost-effective R&D services.

此博客中的热门博文

The Launch Meeting was Held by Medicilon and DAC Biotech of the Contract Research on ADC Preclinical Study

Chuansha, Shanghai, Nov. 8th, 2019 — Medicilon held the launch meeting with Hangzhou DAC Biotech Co., Ltd to initiate the preclinical study of the antibody-drug-conjugate (ADC) DXC005, including the pharmacology study , DMPK study and the safety evaluation . Medicilon has previously completed integrated preclinical research on ADC drugs cooperating with DAC Biotech and other companies. Two of them has been approved by NMPA and entered Phase I clinical trials. About Hangzhou DAC Biotech Co., Ltd Hangzhou DAC Biotech, Co., Ltd was officially registered in HEDA Area, Hangzhou City, Zhejiang Province, China around the end of Year 2012, and is located nearby the bank of beautiful Qiantang River. The company focuses on developing conjugate of monoclonal antibody and small molecular cytotoxic drug, both of which are banded together with smart linkers. About Antibody-Drug-Conjugate (ADC) ADCs ...

阅读全文

Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002

On July 20, 2020, DAC Biotech’s new ADC drug development , TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue. It is used to treat Trop2 triple negative breast cancer, small cell lung cancer, non-small cell lung cancer and pancreatic cancer.Trop2 can promote the proliferation, invasion, metastasis and diffusion of tumor cells, and its high expression is closely related to the shortening of survival time and poor prognosis of tumor patients. Therefore, it is of great significance to study anti-tumor drugs targeted by Trop2. Reference: Medicilon Assists - The first China-made targeting folic acid receptor FRα ADC injection BAT8006 was approved for clinical use Medicilon As...

阅读全文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration. The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies, ADCs , mRNA vaccines , small nucleic acid drugs , PROTAC , and CGT technical service platform that have helped 421 INDs obtain clinical approval. It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

阅读全文

Shanghai Medicilon Inc.

搜索此博客